National practice patterns and direct medical costs for prostate cancer in Korea across a 10 year period: A nationwide population-based study using a national health insurance database

Ho Won Kang, Seok Joong Yun, Jae Il Chung, Hoon Choi, Jae Heon Kim, Ho Song Yu, Yun Sok Ha, In Chang Cho, Hyung Joon Kim, Hyun Chul Chung, Jun Sung Koh, Wun Jae Kim, Jong Hyock Park, Ji Youl Lee, So Young Kim

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background: A complete enumeration study was conducted to evaluate trends in national practice patterns and direct medical costs for prostate cancer (PCa) in Korea over a 10-year retrospective period using data from the Korean National Health Insurance Service. Methods: Reimbursement records for 874,924 patients diagnosed between 2002 and 2014 with primary PCa according to the International Classification of Disease (ICD) 10th revision code C61 were accessed. To assess direct medical costs for patients newly diagnosed after 2005, data from 68,596 patients managed between January 2005 and 31 December 2014 were evaluated. Results: From 2005 to 2014, the total number of PCa patients showed a 2.6-fold increase. Surgery and androgen deprivation therapy were the most common first-line treatment, alone or within the context of combined therapy. Surgery as a monotherapy was performed in 23.5% of patients in 2005, and in 39.4% of patients in 2014. From 2008, the rate of robot-assisted RP rose sharply, showing a similar rate to open RP in 2014. Average total treatment costs in the 12 months post-diagnosis were around 10 million Korean won. Average annual treatment costs thereafter were around 5 million Korean won. Out-of-pocket expenditure was highest in the first year post-diagnosis, and ranged from 12 to 17% thereafter. Conclusions: Between 2005 and 2014, a substantial change was observed in the national practice pattern for PCa in Korea. The present data provide a reliable overview of treatment patterns and medical costs for PCa in Korea.

Original languageEnglish
Article number408
JournalBMC Health Services Research
Volume19
Issue number1
DOIs
Publication statusPublished - 2019 Jun 24

Fingerprint

National Health Programs
Korea
Prostatic Neoplasms
Databases
Costs and Cost Analysis
Population
Health Care Costs
International Classification of Diseases
Therapeutics
Health Expenditures
Androgens

Keywords

  • Costs
  • National Health Insurance
  • Prostatectomy
  • Prostatic neoplasms
  • Radiotherapy

ASJC Scopus subject areas

  • Health Policy

Cite this

National practice patterns and direct medical costs for prostate cancer in Korea across a 10 year period : A nationwide population-based study using a national health insurance database. / Kang, Ho Won; Yun, Seok Joong; Chung, Jae Il; Choi, Hoon; Kim, Jae Heon; Yu, Ho Song; Ha, Yun Sok; Cho, In Chang; Kim, Hyung Joon; Chung, Hyun Chul; Koh, Jun Sung; Kim, Wun Jae; Park, Jong Hyock; Lee, Ji Youl; Kim, So Young.

In: BMC Health Services Research, Vol. 19, No. 1, 408, 24.06.2019.

Research output: Contribution to journalArticle

Kang, Ho Won ; Yun, Seok Joong ; Chung, Jae Il ; Choi, Hoon ; Kim, Jae Heon ; Yu, Ho Song ; Ha, Yun Sok ; Cho, In Chang ; Kim, Hyung Joon ; Chung, Hyun Chul ; Koh, Jun Sung ; Kim, Wun Jae ; Park, Jong Hyock ; Lee, Ji Youl ; Kim, So Young. / National practice patterns and direct medical costs for prostate cancer in Korea across a 10 year period : A nationwide population-based study using a national health insurance database. In: BMC Health Services Research. 2019 ; Vol. 19, No. 1.
@article{a823fa7621064869b681335b649da1ec,
title = "National practice patterns and direct medical costs for prostate cancer in Korea across a 10 year period: A nationwide population-based study using a national health insurance database",
abstract = "Background: A complete enumeration study was conducted to evaluate trends in national practice patterns and direct medical costs for prostate cancer (PCa) in Korea over a 10-year retrospective period using data from the Korean National Health Insurance Service. Methods: Reimbursement records for 874,924 patients diagnosed between 2002 and 2014 with primary PCa according to the International Classification of Disease (ICD) 10th revision code C61 were accessed. To assess direct medical costs for patients newly diagnosed after 2005, data from 68,596 patients managed between January 2005 and 31 December 2014 were evaluated. Results: From 2005 to 2014, the total number of PCa patients showed a 2.6-fold increase. Surgery and androgen deprivation therapy were the most common first-line treatment, alone or within the context of combined therapy. Surgery as a monotherapy was performed in 23.5{\%} of patients in 2005, and in 39.4{\%} of patients in 2014. From 2008, the rate of robot-assisted RP rose sharply, showing a similar rate to open RP in 2014. Average total treatment costs in the 12 months post-diagnosis were around 10 million Korean won. Average annual treatment costs thereafter were around 5 million Korean won. Out-of-pocket expenditure was highest in the first year post-diagnosis, and ranged from 12 to 17{\%} thereafter. Conclusions: Between 2005 and 2014, a substantial change was observed in the national practice pattern for PCa in Korea. The present data provide a reliable overview of treatment patterns and medical costs for PCa in Korea.",
keywords = "Costs, National Health Insurance, Prostatectomy, Prostatic neoplasms, Radiotherapy",
author = "Kang, {Ho Won} and Yun, {Seok Joong} and Chung, {Jae Il} and Hoon Choi and Kim, {Jae Heon} and Yu, {Ho Song} and Ha, {Yun Sok} and Cho, {In Chang} and Kim, {Hyung Joon} and Chung, {Hyun Chul} and Koh, {Jun Sung} and Kim, {Wun Jae} and Park, {Jong Hyock} and Lee, {Ji Youl} and Kim, {So Young}",
year = "2019",
month = "6",
day = "24",
doi = "10.1186/s12913-019-4218-7",
language = "English",
volume = "19",
journal = "BMC Health Services Research",
issn = "1472-6963",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - National practice patterns and direct medical costs for prostate cancer in Korea across a 10 year period

T2 - A nationwide population-based study using a national health insurance database

AU - Kang, Ho Won

AU - Yun, Seok Joong

AU - Chung, Jae Il

AU - Choi, Hoon

AU - Kim, Jae Heon

AU - Yu, Ho Song

AU - Ha, Yun Sok

AU - Cho, In Chang

AU - Kim, Hyung Joon

AU - Chung, Hyun Chul

AU - Koh, Jun Sung

AU - Kim, Wun Jae

AU - Park, Jong Hyock

AU - Lee, Ji Youl

AU - Kim, So Young

PY - 2019/6/24

Y1 - 2019/6/24

N2 - Background: A complete enumeration study was conducted to evaluate trends in national practice patterns and direct medical costs for prostate cancer (PCa) in Korea over a 10-year retrospective period using data from the Korean National Health Insurance Service. Methods: Reimbursement records for 874,924 patients diagnosed between 2002 and 2014 with primary PCa according to the International Classification of Disease (ICD) 10th revision code C61 were accessed. To assess direct medical costs for patients newly diagnosed after 2005, data from 68,596 patients managed between January 2005 and 31 December 2014 were evaluated. Results: From 2005 to 2014, the total number of PCa patients showed a 2.6-fold increase. Surgery and androgen deprivation therapy were the most common first-line treatment, alone or within the context of combined therapy. Surgery as a monotherapy was performed in 23.5% of patients in 2005, and in 39.4% of patients in 2014. From 2008, the rate of robot-assisted RP rose sharply, showing a similar rate to open RP in 2014. Average total treatment costs in the 12 months post-diagnosis were around 10 million Korean won. Average annual treatment costs thereafter were around 5 million Korean won. Out-of-pocket expenditure was highest in the first year post-diagnosis, and ranged from 12 to 17% thereafter. Conclusions: Between 2005 and 2014, a substantial change was observed in the national practice pattern for PCa in Korea. The present data provide a reliable overview of treatment patterns and medical costs for PCa in Korea.

AB - Background: A complete enumeration study was conducted to evaluate trends in national practice patterns and direct medical costs for prostate cancer (PCa) in Korea over a 10-year retrospective period using data from the Korean National Health Insurance Service. Methods: Reimbursement records for 874,924 patients diagnosed between 2002 and 2014 with primary PCa according to the International Classification of Disease (ICD) 10th revision code C61 were accessed. To assess direct medical costs for patients newly diagnosed after 2005, data from 68,596 patients managed between January 2005 and 31 December 2014 were evaluated. Results: From 2005 to 2014, the total number of PCa patients showed a 2.6-fold increase. Surgery and androgen deprivation therapy were the most common first-line treatment, alone or within the context of combined therapy. Surgery as a monotherapy was performed in 23.5% of patients in 2005, and in 39.4% of patients in 2014. From 2008, the rate of robot-assisted RP rose sharply, showing a similar rate to open RP in 2014. Average total treatment costs in the 12 months post-diagnosis were around 10 million Korean won. Average annual treatment costs thereafter were around 5 million Korean won. Out-of-pocket expenditure was highest in the first year post-diagnosis, and ranged from 12 to 17% thereafter. Conclusions: Between 2005 and 2014, a substantial change was observed in the national practice pattern for PCa in Korea. The present data provide a reliable overview of treatment patterns and medical costs for PCa in Korea.

KW - Costs

KW - National Health Insurance

KW - Prostatectomy

KW - Prostatic neoplasms

KW - Radiotherapy

UR - http://www.scopus.com/inward/record.url?scp=85068178955&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85068178955&partnerID=8YFLogxK

U2 - 10.1186/s12913-019-4218-7

DO - 10.1186/s12913-019-4218-7

M3 - Article

C2 - 31234845

AN - SCOPUS:85068178955

VL - 19

JO - BMC Health Services Research

JF - BMC Health Services Research

SN - 1472-6963

IS - 1

M1 - 408

ER -